Scarica l'app Stockscreener
3.32
3.49%
-0.12
Dopo l'orario di chiusura:
3.38
0.06
+1.81%
Quantum Biopharma Ltd Borsa (QNTM) Ultime notizie
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - TradingView
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - TipRanks
Quantinuum (QNTM) Receives Strong Ratings, Shares Rise 5% in Pre-Market - GuruFocus
Quantum Biopharma Q4 2025 Earnings: Reports net loss of $0.71 per share as clinical‑stage biotech continues operationsFinancial Summary - dars.gov.et
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
Quantum BioPharma's Lucid-MS Targets Underlying Cause of Multiple Sclerosis in Growing $38.6B Market - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (NASDAQ:QNTM) - TradingView
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum BioPharma’s Lucid-MS Aims to Fill Void in Multiple Sclerosis Treatment - citybuzz -
Quantum BioPharma’s MS drug targets myelin as phase 2 nears - Stock Titan
Quantum BioPharma Company Profile & Introduction - Moomoo
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis - citybuzz -
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAM:0K91 - TradingView
The Quest to Repair What Multiple Sclerosis Takes Away - Caledon Enterprise
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - Sahm
Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - TipRanks
Quantum BioPharma's Lucid-MS Candidate Highlighted for Potential to Address Unmet Need in Multiple Sclerosis Treatment - citybuzz -
Quantum BioPharma's Bid to Repair MS, Not Just Manage It - BriefGlance
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, - GlobeNewswire
QNTM News | QUANTUM BIOPHARMA-B SUB VOT (NASDAQ:QNTM) - ChartMill
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - citybuzz -
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quantum BioPharma Ltd (QNTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quantum BioPharma Ltd (QNTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
Quantum BioPharma Ltd (QNTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QNTM Q4 2025 Earnings: Net Loss Widens as Biotech Advances Pipeline Without RevenueCapex Guidance - lwvtexas.org
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss per Share; Stock Gains $1.78GAAP Earnings Report - newsline.com
QNTM Q4 2025 Earnings: Loss per Share Reported as Revenue Remains UnreportedMid-Term Outlook - dars.gov.et
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment - TradingView
CSE Filings for Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Advances Lucid-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial - citybuzz -
Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Ltd. Subordinate Voting Shares - The Canadian Securities Exchange (CSE)
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast - NewMediaWire
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - TipRanks
Quantum BioPharma Hires Stocks.news for Investor Relations Services in $250,000 Deal - citybuzz -
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate and Alcohol Metabolism Product - citybuzz -
Quantum BioPharma Hit by FDA Clinical Hold on Lead MS Drug as Director Resigns - TipRanks
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):